Pulmonary Hypertension: Clinical Trials

303 completed, 100 unknown, 96 recruiting, 65 terminated. 149 Not applicable, 112 Phase 2, 78 Phase 3, 44 Phase 1, 34 Phase 4.

By phase and status

Phase	Trials	Status
Not applicable	149	Completed 70, Unknown 33, Recruiting 22, Terminated 10, Withdrawn 6, Enrolling by invitation 3, Active not recruiting 2, Not yet recruiting 2, Suspended 1
Phase 2	112	Completed 54, Terminated 19, Withdrawn 11, Recruiting 10, Unknown 10, Active not recruiting 4, Not yet recruiting 4
Phase 3	78	Completed 38, Terminated 17, Unknown 10, Recruiting 5, Withdrawn 4, Active not recruiting 2, Enrolling by invitation 1, Not yet recruiting 1
Phase 1	44	Completed 21, Terminated 6, Withdrawn 6, Recruiting 5, Not yet recruiting 3, Unknown 3
Phase 4	34	Completed 16, Terminated 8, Unknown 4, Withdrawn 3, Active not recruiting 1, Not yet recruiting 1, Recruiting 1
Early Phase 1	8	Terminated 3, Recruiting 2, Not yet recruiting 1, Unknown 1, Withdrawn 1

Follow Pulmonary Hypertension: new trials by email Literature Review of Pulmonary Hypertension trials Research Report on Pulmonary Hypertension

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
GLP-1/GIP Receptor Agonists in Obesity-Related HFpEF: The GLIDE-HF Registry GLP-1 / GIP receptor agonist - Heart Failure With Preserved Ejection Fraction, Obesity		Not yet recruiting	Miedziowe Centrum Zdrowia SA	150	2027-01-01	2026-08-26
Right Heart and Lung Blood Flow During Exercise (RIGHT-NET 2.0) Right Ventricular Dysfunction, Cardiopulmonary Diseases		Not yet recruiting	IRCCS SYNLAB SDN	2000	2027-01-01	2026-10-01
Bridge to Lung Transplant With Trans-septal Extra-corporeal Membrane Oxygenation (ECMO) for Right Heart Failure From Pulmonary Hypertension Protek Solo Transseptal Cannula - Lung Transplant, Pulmonary Hypertension	Phase 1	Recruiting	Mayo Clinic	4	2026-12-11	2026-07-31
A Clinical Study of Sotatercept (MK-7962) in People With Combined Postcapillary and Precapillary Pulmonary Hypertension and Heart Failure With Preserved Ejection Fraction (MK-7962-041) Sotatercept, Placebo - Pulmonary Hypertension	Phase 3	Not yet recruiting	Merck Sharp & Dohme LLC	352	2026-11-26	2026-10-23
Hyperpolarized Xenon MRI in Adults With Pulmonary Hypertension in Interstitial Lung Disease and Systemic Sclerosis Hyperpolarized 129 Xenon Gas - Interstitial Lung Disease, Pulmonary Hypertension	Phase 2	Not yet recruiting	Bastiaan Driehuys	51	2026-11-01	2026-09-15
TEPH: Telaglenastat Efficacy in Pulmonary Hypertension Telaglenastat - Pulmonary Hypertension	Phase 1 / Phase 2	Not yet recruiting	Chan, Stephen, MD, PhD	28	2026-11-01	2026-09-17
Pulmonary Hypertension (PH) Biorepository for Translational Research Pulmonary Hypertension		Recruiting	National Institutes of Health Clinical Center (CC)	1000	2026-10-19	2026-10-22
Pulmonary Hypertension and Oxygen Saturation Targeting in Preterm Infants higher oxygen saturation target using Nellcor pulse oximetry sensors, lower oxygen saturation target using Nellcor pulse oximetry sensors - Bronchopulmonary Dysplasia, Pulmonary Hypertension	Not applicable	Recruiting	University of Alabama at Birmingham	39	2026-09-22	2026-10-06
Pulmonary Hypertension and RV Dysfunction in Myeloproliferative Neoplasms Myeloproliferative Neoplasm, Right Ventricular Dysfunction		Not yet recruiting	Assiut University	145	2026-09-20	2026-09-22
Multimodal Physiologic State Intelligence Study OMNIPHYS Multimodal Ultrasound Imaging System - Heart Failure, Cardiomyopathies		Enrolling by invitation	Truway Health, Inc.	25000	2026-09-02	2026-09-10
Early Intervention With Inhaled Treprostinil Among Patients With Exercise-Induced Pulmonary Hypertension (EPIH) Treprostinil, Standard of Care - Pulmonary Hypertension	Early Phase 1	Recruiting	Valley Health System	32	2026-09-01	2026-09-24
HS235 Study in Overweight and Obese Participants With Combined Pre and Post-Capillary Pulmonary Hypertension Due to Heart Failure With Preserved Ejection Fraction HS235, Placebo - Pulmonary Hypertension, Heart Failure With Preserved Ejection Fraction	Phase 1 / Phase 2	Recruiting	35Pharma Inc	126	2026-09-01	2026-09-29
Self-Help Booklets for Sleep in Adults With Pulmonary Hypertension Sleep Hygiene Self-Help Intervention - Pulmonary Hypertension, Insomnia	Not applicable	Not yet recruiting	University of Sheffield	60	2026-09-01	2026-08-10
Dynamic Changes in Right Ventricle and Pulmonary Artery Coupling Among COPD Patients With Acute Exacerbation Echocardiography assessment - COPD Exacerbation (AECOPD), Pulmonary Hypertension		Not yet recruiting	Assiut University	115	2026-09-01	2026-07-10
A Phase 3 Trial of Inhaled Mosliciguat in PH-ILD (PHrontier) Mosliciguat, Placebo, Dry Powder Inhaler - Pulmonary Hypertension, Interstitial Lung Disease	Phase 3	Recruiting	Pulmovant, Inc.	376	2026-08-31	2026-09-11
A Randomized Placebo-procedure Controlled Trial of the Enhancor System (PULmonary Artery Denervation) to Evaluate Safety and Efficacy in Patients With Combined Pre- and Post-capillary Pulmonary Hypertension Associated With Left Heart Disease Pulmonary Artery Denervation (PADN), Sham procedure control - Pulmonary Hypertension, Heart Failure With Reduced Ejection Fraction	Not applicable	Recruiting	Pulnovo Medical, Inc.	750	2026-08-21	2026-10-20
Effect of Vasopressin Versus Norepinephrine on Post-operative Mean Pulmonary Arterial Pressure Following Pulmonary Endarterectomy Surgery, Vasopressin, Norepinephrine - Anesthesia, Pulmonary Hypertension	Phase 2	Not yet recruiting	Fondation Hôpital Saint-Joseph	90	2026-08-01	2026-06-02
Wearable Assessment of Thoracic, Cardiac Health and Exercise Performance Trial Prospective Apple Watch Series 9 - Congenital Heart Disease, Pulmonary Hypertension		Not yet recruiting	The University of Hong Kong	20	2026-08-01	2026-06-23
An Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD) Treprostinil Palmitil Inhalation Powder, Placebo - Pulmonary Hypertension, Interstitial Lung Disease	Phase 3	Recruiting	Insmed Incorporated	344	2026-07-20	2026-08-13
The Benefits of Home Exercise in Pulmonary Hypertension Interstitial Lung Disease Home Exercise Program, Aerobic Plus Strength Training, Home Exercise Program, Aerobic Only - Pulmonary Hypertension, Interstitial Lung Disease	Not applicable	Recruiting	University of Rochester	30	2026-07-15	2026-07-24

Showing 20 of 660. Sign in to see all of them.

Narrower conditions

Hypertension, Pulmonary (660)  ·  Pulmonary Arterial Hypertension (76)  ·  Heart Failure (50)  ·  Pulmonary Disease, Chronic Obstructive (46)  ·  Lung Diseases, Interstitial (36)  ·  Anemia, Sickle Cell (22)  ·  Scleroderma, Systemic (19)  ·  Motor Activity (18)  ·  Heart Defects, Congenital (17)  ·  Lung Diseases (17)  ·  Cardiovascular Diseases (16)  ·  Familial Primary Pulmonary Hypertension (15)  ·  Pulmonary Fibrosis (15)  ·  Hypertension (14)  ·  Pulmonary Embolism (12)

Broader conditions

Respiratory Tract Diseases (655)  ·  Vascular Diseases (651)  ·  Hypertension (646)  ·  Cardiovascular Diseases (644)  ·  Lung Diseases (643)  ·  Pathological Conditions, Signs and Symptoms (125)  ·  Pathologic Processes (103)  ·  Heart Diseases (102)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (78)  ·  Disease Attributes (59)  ·  Chronic Disease (52)  ·  Lung Diseases, Obstructive (47)  ·  Hemic and Lymphatic Diseases (42)  ·  Respiration Disorders (36)  ·  Genetic Diseases, Inborn (35)

Interventions

Sildenafil Citrate (34)  ·  treprostinil (22)  ·  Iloprost (17)  ·  ambrisentan (15)  ·  Bosentan (13)  ·  Echocardiography (12)  ·  Exercise (11)  ·  Tadalafil (10)  ·  Exercise Test (6)  ·  Blood Specimen Collection (5)  ·  Nitric Oxide (5)  ·  Saline Solution (5)  ·  Sodium Chloride (5)  ·  Cardiac Catheterization (4)  ·  Milrinone (4)

Sponsors

University of Zurich (24)  ·  United Therapeutics (22)  ·  Medical University of Graz (16)  ·  Actelion (14)  ·  Assiut University (13)  ·  National Heart, Lung, and Blood Institute (NHLBI) (13)  ·  University of Giessen (11)  ·  Heidelberg University (10)  ·  Assistance Publique - Hôpitaux de Paris (8)  ·  Mayo Clinic (8)  ·  Bayer (7)  ·  Gilead Sciences (7)  ·  Chinese Pulmonary Vascular Disease Research Group (6)  ·  Echosense Ltd. (6)  ·  University of Colorado, Denver (6)

Countries

United States (250)  ·  Germany (66)  ·  China (56)  ·  United Kingdom (56)  ·  France (50)  ·  Canada (42)  ·  Austria (40)  ·  Switzerland (38)  ·  Italy (36)  ·  Spain (34)  ·  Belgium (32)  ·  Israel (29)  ·  Australia (24)  ·  Turkey (Türkiye) (24)  ·  Brazil (22)

Top investigators

Silvia Ulrich, Prof. (15)  ·  Horst Olschewski, MD (11)  ·  Ashika Ahmed, MD (5)  ·  Rajan Saggar, MD (4)  ·  Barry Borlaug, MD (3)  ·  Jeffrey Feinstein, MD, MPH (3)  ·  John F Tisdale, M.D. (3)  ·  Silvia Ulrich, MD (3)  ·  Swee Lay Thein, M.D. (3)  ·  Werner Seeger, MD (3)  ·  Yuchi Han, MD (3)

Results publications

PMID 20175775, PMID 24578332, PMID 26589907, PMID 27162632, PMID 16982941, PMID 23883377, PMID 23883383, PMID 24916507, PMID 25372980, PMID 25496504, PMID 27067478, PMID 27263466, PMID 27326239, PMID 27444506, PMID 29531764, PMID 31487545, PMID 31722151, PMID 32974687, PMID 34353714, PMID 34848133, PMID 35256218, PMID 35628896, PMID 35990987, PMID 36713022, PMID 36858690, PMID 38768982, PMID 41627369, PMID 10966311, PMID 12873568, PMID 16446108, PMID 16487841, PMID 16703233, PMID 16717171, PMID 1682593, PMID 17338847, PMID 17536019, PMID 17556308, PMID 18274461, PMID 18277824, PMID 18506008, PMID 18572079, PMID 18752852, PMID 18790440, PMID 18812445, PMID 18824488, PMID 18977464, PMID 19215832, PMID 19318356, PMID 19344390, PMID 19470885

NIH funding

2018 (17), 2025 (7), 2008 (4), 2014 (2), U10HD021385 (2), U10HD027880 (2), U10HD034216 (2), U10HD036790 (2), U10HD040492 (2), U10HD040689 (2), U10HD053109 (2), 1UM1HL113115-01A1 (1), 2009 (1), 2016 (1), 2023 (1)